Title : A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

Pub. Date : 2003 Oct 15

PMID : 12843001






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This concept represented the rationale for the initiation of a multicenter phase 2 trial of SU5416, a small molecule inhibitor of phosphorylation of VEGF receptors 1 and 2, c-kit, the SCF receptor, and fms-like tyrosine kinase-3 (FLT3) in patients with advanced AML. Semaxinib fms related receptor tyrosine kinase 3 Homo sapiens
2 This concept represented the rationale for the initiation of a multicenter phase 2 trial of SU5416, a small molecule inhibitor of phosphorylation of VEGF receptors 1 and 2, c-kit, the SCF receptor, and fms-like tyrosine kinase-3 (FLT3) in patients with advanced AML. Semaxinib fms related receptor tyrosine kinase 3 Homo sapiens